Results 41 to 50 of about 157,671 (305)
Vacuna COVID-19 Oxford /AstraZeneca - Vaxzevria: guia ràpida [cartell]
, 2021 Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Vaccine; Oxford / AstraZeneca-Vaxzevria; IndicationsCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Vacuna; Oxford / AstraZeneca-Vaxzevria; IndicacionsCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Vacuna; Oxford /
core
Molecular Oncology, EarlyView.We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu +10 more
wiley +1 more source
Infection and Drug Resistance, 2021 Mahmoodullah Azimi,1 Wazhma Masoom Dehzad,1 Mohammad Asif Atiq,1 Barin Bahain,1 Abdullah Asady2 1Department of Clinical Pharmacology, Kabul University of Medical Sciences, Kabul, Afghanistan; 2Department of Microbiology, Kabul University of Medical ...
Azimi M +4 more
doaj
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
COVID-19 Vaccine Perception in South Korea: Web Crawling Approach
JMIR Public Health and Surveillance, 2021 BackgroundThe US Centers for Disease Control and Prevention and the World Health Organization emphasized vaccination against COVID-19 because physical distancing proved inadequate to mitigate death, illness, and massive economic ...
Hocheol Lee +6 more
doaj +1 more source
AstraZeneca's compound interest [PDF]
Science-Business eXchange, 2012 The U.K.'s Medical Research Council has partnered with AstraZeneca to make the pharma's shelved compounds available to academics investigating basic disease mechanisms. A first call for proposals is in progress.
openaire +1 more source
Results of meta-regression including AstraZeneca as a dummy variable.
, 2022 Results of meta-regression including AstraZeneca as a dummy variable.
Rajeev Sharma (3541484) +1 more
core +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source